Clinical trial · Interventional
EUS-guided Ethanol Ablation of an Insulinoma
Endoscopic Ultrasound (EUS)-Guided Ethanol Ablation of an Insulinoma - A Multi-center Prospective Cohort Study
NCT02121366CI-TRIAL-00014322EUSunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study aims to evaluate the feasibility, safety and efficacy of EUS-guided ethanol ablation of an insulinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Insulinoma | Pancreatic Insulinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-guided ethanol ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Insulinoma
- description
- Patients with Insulinomas will received EUS-guided ethanol ablation therapy
- interventionNames
- Procedure: EUS-guided ethanol ablation
Primary outcomes (2)
- measure
- Efficacy of EUS-guided ethanol ablation
- timeFrame
- 1 to 12 month
- description
- Volumes of insulinomas before and after treatment, which are measured by cross-sectional imaging test (CT or MRS).
- measure
- Safety of EUS-guided ethanol ablation
- timeFrame
- 1 to 12 month
- description
- Number of subjects with post-procedure adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults: at least 18 years. 2. Patients with insulinomas which are evaluated by histopathology . 3. patients who have signed a written consent form. Exclusion Criteria: 1. Patients whose condition is not suitable for the endoscopic procedure. 2. Patients who have blood coagulation dysfunction. 3. Patients who have mental disorders. 4. Patients who have mild or severe cardiorespiratory insufficiency. 5. Patients who have hypertension and could not be controlled to safe level. 6. Pregnant and lactating women. 7. Patients whose conditions are not suitable for the present study.
References
Publications (0)
Data not yet available
No reference posted for this study.